Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

Author:

Verardi Fabio12ORCID,Maul Lara Valeska123,Borsky Kim4,Steinmann Simona12,Rosset Nina1,Pons Hector Ortega5,Sorbe Christina6ORCID,Yawalkar Nikhil7ORCID,Micheroli Raphael8,Egeberg Alexander910ORCID,Thyssen Jacob P.910,Heidemeyer Kristine7ORCID,Boehncke Wolf‐Henning11,Conrad Curdin12ORCID,Cozzio Antonio13,Pinter Andreas14ORCID,Kündig Thomas1,Navarini Alexander A.3ORCID,Maul Julia‐Tatjana12ORCID

Affiliation:

1. Department of Dermatology University Hospital Zurich Zurich Switzerland

2. Faculty of Medicine University of Zurich Zurich Switzerland

3. Department of Dermatology University Hospital Basel Basel Switzerland

4. Oxford School of Surgery Oxford Business Park Oxford UK

5. Swiss4ward, Statistician and Data Analyst Zurich Switzerland

6. Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

7. Department of Dermatology, Inselspital, Bern University Hospital University of Bern Bern Switzerland

8. Department of Rheumatology, University Hospital Zurich University of Zurich Zurich Switzerland

9. Department of Dermato‐Venereology and Wound Healing Centre Copenhagen University Hospital Bispebjerg Copenhagen Denmark

10. Department of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

11. Division of Dermatology and Venereology Geneva University Hospitals Geneva Switzerland

12. Department of Dermatology CHUV University Hospital and University of Lausanne (UNIL) Lausanne Switzerland

13. Clinic of Dermatology, Venereology and Allergology Cantonal Hospital St. Gallen St. Gallen Switzerland

14. Department of Dermatology, Venerology and Allergology University Hospital Frankfurt am Main Frankfurt am Main Germany

Abstract

AbstractBackgroundPsoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex‐specific differences in the safety of systemic psoriasis therapies.ObjectivesTo examine the real‐world, long‐term safety of systemic psoriasis therapies with sex stratification in drug‐related adverse events (ADRs).MethodsTen‐year data from adults with moderate‐to‐severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient‐years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t‐tests to compare treatment groups and sex.ResultsIn total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2‐fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0‐fold higher drug‐related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non‐significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87–9.68) compared to CSTs (7.08, CI 5.39–9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8‐fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0‐fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug‐related discontinuation rates for most CSTs in females.ConclusionFemales were associated with a significantly higher rate of ADRs and drug‐related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient‐tailored management of psoriasis.

Funder

AbbVie

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3